Literature DB >> 8182003

In-vitro activity of five beta-lactam/beta-lactamase inhibitor combinations against consecutive isolates of the Enterobacteriaceae and Pseudomonas aeruginosa.

J C McLaughlin1, A L Barry, P C Fuchs, E H Gerlach, D J Hardy, M A Pfaller.   

Abstract

Susceptibility tests were performed on 2402 of consecutive isolates of Enterobacteriaceae and 254 strains of Pseudomonas aeruginosa in five separate medical centres. Five beta-lactams were evaluated with and without a beta-lactamase inhibitor. The effect of different inhibitors was species specific and the rank order of decreasing efficacy against all enteric bacilli was: cefoperazone-sulbactam > piperacillin-tazobactam > cefoperazone > ticarcillin-clavulanic acid > piperacillin > co-amoxiclav > ampicillin-sulbactam > ticarcillin > ampicillin > amoxycillin.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8182003     DOI: 10.1093/jac/33.2.223

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  2 in total

Review 1.  Beta-lactam/beta-lactamase inhibitor combinations: development, antibacterial activity and clinical applications.

Authors:  R Sutherland
Journal:  Infection       Date:  1995 Jul-Aug       Impact factor: 3.553

2.  Beta-lactamase inhibitors are substrates for the multidrug efflux pumps of Pseudomonas aeruginosa.

Authors:  X Z Li; L Zhang; R Srikumar; K Poole
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.